Moderna Submits Request for Emergency Use of COVID-19 Vaccine for Young Children
The KidCOVE study included children 6 months to less than 6 years of age who received either two 25mcg doses of mRNA-1273 or placebo, separated by 28 days.
The KidCOVE study included children 6 months to less than 6 years of age who received either two 25mcg doses of mRNA-1273 or placebo, separated by 28 days.
About 60 percent of Israel’s 9.4 million people are fully vaccinated with either a recent second dose or booster dose
Mean levels of anti-Müllerian hormone unchanged from baseline to three months after vaccination among reproductive-aged women
After two-dose vaccination, only 64 and 67 percent of kidney transplant recipients showed neutralization against B.1.351 (β) and B.1.617.2 (δ)
Estimated vaccine effectiveness of full Pfizer-BioNTech vaccination 92 percent for preventing SARS-CoV-2 infection
Study conducted in the U.S. and Mexico shows vaccine 90 percent effective overall, 100 percent effective against moderate-to-severe disease
Agency also reduced the period people must wait between their second dose and booster shot from six to five months
At ≥7 days after second dose, effectiveness of mRNA COVID-19 vaccine was 69 percent against infection, 86 percent against related death
Country-specific information, such as prior vaccination uptake, vaccine hesitancy may influence the effect of COVID-19 certification mandates
Molnupiravir cut the risk for hospitalization and death in high-risk patients by 30 percent